A Prescription for Precision: Integrating Genetics into Essential Medicines Lists
A new analysis scrutinizes the World Health Organization and African national Essential Medicines Lists (EMLs), which are designed to guide treatment decisions by ensuring the availability of key drugs. The study reveals a significant gap: these lists currently do not account for actionable pharmacogenomic biomarkers, despite the well-documented influence of genetics on drug efficacy and safety. This oversight is particularly critical for Africa, a continent with immense genetic diversity, where the use of standard drug lists without genetic guidance may lead to suboptimal patient outcomes.
Continue reading to unlock the full analysis, deeper implications, and why this study may matter for your field.
Unlock Full Briefing — 50% Off with Coupon: ERWMCWYU
Full version includes the complete summary, study significance, and direct link to the original source.
Stay curious. Stay informed — with Science Briefing.
This is a preview briefing. Upgrade to access the full version.
